Autor: |
Gérard A; HiFiBiO Therapeutics SAS, Paris, France., Woolfe A; HiFiBiO Therapeutics SAS, Paris, France., Mottet G; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France., Reichen M; HiFiBiO Therapeutics SAS, Paris, France., Castrillon C; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.; École Doctorale Frontières du Vivant (FdV), Centre de Recherches Interdisciplinaires, Paris, France.; Laboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France., Menrath V; HiFiBiO Therapeutics SAS, Paris, France., Ellouze S; HiFiBiO Therapeutics SAS, Paris, France., Poitou A; HiFiBiO Therapeutics SAS, Paris, France., Doineau R; HiFiBiO Therapeutics SAS, Paris, France.; École Doctorale Frontières du Vivant (FdV), Centre de Recherches Interdisciplinaires, Paris, France.; Laboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France.; Institute for Integrative Nanosciences, Leibniz IFW Dresden e.V., Dresden, Germany., Briseno-Roa L; HiFiBiO Therapeutics SAS, Paris, France.; Medetia Pharma, Institut Imagine, Paris, France., Canales-Herrerias P; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.; École Doctorale Frontières du Vivant (FdV), Centre de Recherches Interdisciplinaires, Paris, France.; Laboratoire Colloïdes et Matériaux Divisés (LCMD), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France., Mary P; HiFiBiO Therapeutics Inc., Cambridge, MA, USA., Rose G; HiFiBiO Therapeutics Inc., Cambridge, MA, USA., Ortega C; HiFiBiO Therapeutics Inc., Cambridge, MA, USA., Delincé M; HiFiBiO Therapeutics Inc., Cambridge, MA, USA., Essono S; HiFiBiO Therapeutics Inc., Cambridge, MA, USA., Jia B; Pfizer, Cambridge, MA, USA.; Abbvie Bioresearch Center, Worcester, MA, USA., Iannascoli B; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France., Richard-Le Goff O; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France., Kumar R; HiFiBiO Therapeutics Inc., Cambridge, MA, USA., Stewart SN; HiFiBiO Therapeutics Inc., Cambridge, MA, USA., Pousse Y; HiFiBiO Therapeutics SAS, Paris, France., Shen B; HiFiBiO Therapeutics SAS, Paris, France., Grosselin K; HiFiBiO Therapeutics SAS, Paris, France.; Laboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France., Saudemont B; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.; Laboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France., Sautel-Caillé A; Laboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France., Godina A; Laboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France., McNamara S; HiFiBiO Therapeutics SAS, Paris, France., Eyer K; Laboratoire Colloïdes et Matériaux Divisés (LCMD), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France.; Laboratory for Functional Immune Repertoire Analysis, Institute of Pharmaceutical Sciences, D-CHAB, ETH Zürich, Zurich, Switzerland., Millot GA; Institut Pasteur, Hub Bioinformatique et Biostatistique, C3BI, USR 3756 IP CNRS, Paris, France., Baudry J; Laboratoire Colloïdes et Matériaux Divisés (LCMD), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France., England P; Plateforme de Biophysique Moléculaire, Institut Pasteur, CNRS UMR3528, Paris, France.; Centre d'Innovation et de Technologie, Plateforme de Biophysique des Macromolecules et de leurs Interactions, Institut Pasteur, Paris, France., Nizak C; Laboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France., Jensen A; HiFiBiO Therapeutics SAS, Paris, France.; Lundbeck A/S, Valby, Denmark., Griffiths AD; Laboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France. andrew.griffiths@espci.fr., Bruhns P; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France. pierre.bruhns@pasteur.fr., Brenan C; HiFiBiO Therapeutics SAS, Paris, France. c.brenan@1cell-bio.com.; HiFiBiO Therapeutics Inc., Cambridge, MA, USA. c.brenan@1cell-bio.com.; 1CellBiO Inc., Watertown, MA, USA. c.brenan@1cell-bio.com. |